Literature DB >> 18023982

In vitro and in vivo characteristics of a thermogelling and bioadhesive delivery system intended for rectal administration of quinine in children.

A A Koffi1, F Agnely, M Besnard, J Kablan Brou, J L Grossiord, G Ponchel.   

Abstract

The aim of this work was to improve the rectal bioavailability of quinine hydrochloride by designing thermosensitive and mucoadhesive gels intended for rectal delivery. The rheological and mucoadhesive properties of poloxamer 407 solutions have been modulated by addition of hydroxypropylmethycellulose (HPMC) and propanediol-1,2. In vitro release and rectal absorption of quinine have been highlighted by a dialysis dissolution testing method and by the determination of bioavailability of the different formulations in rabbits. Increasing the proportions of HPMC and poloxamer in the formulations resulted in a prolonged release of quinine. Indeed, compared to the DT 50% of a rectal solution and a simple HPMC gel (27 and 65 min, respectively) the DT 50% of thermosensitive ternary systems was increased and ranged between 80 and 138 min, depending on the system composition. The release rate depended strongly on the elasticity of the gels after thermogelation. The absolute rectal bioavailability of quinine determined in rabbits was significantly improved with these thermosensitive and adhesive systems. It increased from 62% for the rectal solution to 98% for a ternary system 16/0.5/30 (poloxamer (16%)/HPMC (0.5%)/propanediol-1,2 (30%)). As a result of combined bioadhesion and prolonged release of quinine in vivo, higher average values of MRT and t(max) (9.1+/-0.2h and 30 min, respectively) were obtained compared to the rectal solution (6.9+/-0.9h and 15 min, respectively). Moreover, these formulations presented a very good rectal tolerance. Modulation by HPMC of the viscoelastic and mucoadhesive properties of poloxamer 407 thermogelling solutions allowed a prolonged release of quinine hydrochloride and an improvement of bioavailability in rabbit.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18023982     DOI: 10.1016/j.ejpb.2007.09.017

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

1.  In vitro and in vivo characteristics of a thermogelling rectal delivery system of etodolac.

Authors:  Nahla S Barakat
Journal:  AAPS PharmSciTech       Date:  2009-05-29       Impact factor: 3.246

2.  Preparation, in vitro and in vivo Evaluation of Thermosensitive in situ Gel Loaded with Ibuprofen-Solid Lipid Nanoparticles for Rectal Delivery.

Authors:  Chun-Hui Huang; Peng-Yi Hu; Qiu-Yan Wu; Ming-Yan Xia; Wen-Liu Zhang; Zhi-Qiang Lei; Dong-Xun Li; Guo-Song Zhang; Jian-Fang Feng
Journal:  Drug Des Devel Ther       Date:  2022-05-12       Impact factor: 4.319

3.  Evaluation of epirubicin in thermogelling and bioadhesive liquid and solid suppository formulations for rectal administration.

Authors:  Yu-Li Lo; Yijun Lin; Hong-Ru Lin
Journal:  Int J Mol Sci       Date:  2013-12-31       Impact factor: 5.923

Review 4.  Physiological and Pharmaceutical Considerations for Rectal Drug Formulations.

Authors:  Susan Hua
Journal:  Front Pharmacol       Date:  2019-10-16       Impact factor: 5.810

5.  Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases.

Authors:  Raul Diaz-Salmeron; Balthazar Toussaint; Nicolas Huang; Etienne Bourgeois Ducournau; Gabriel Alviset; Sophie Goulay Dufaÿ; Hervé Hillaireau; Amélie Dufaÿ Wojcicki; Vincent Boudy
Journal:  Pharmaceutics       Date:  2021-01-18       Impact factor: 6.321

6.  Development of in situ gelling and bio adhesive 5-Fluorouracil enema.

Authors:  Lu-Lu Wang; Wen-Sheng Zheng; Shao-Hua Chen; Xia-Qin Fang
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

7.  In situ delivery of thermosensitive gel-mediated 5-fluorouracil microemulsion for the treatment of colorectal cancer.

Authors:  Lu-Lu Wang; Shuai Huang; Hui-Hui Guo; Yan-Xing Han; Wen-Sheng Zheng; Jian-Dong Jiang
Journal:  Drug Des Devel Ther       Date:  2016-09-08       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.